Michael P. Lisanti MD/PhD, FRSA, FRSB, FRSC
President of Lunella Biotech Inc.

Michael P. Lisanti, MD-PhD, FRSA, FRSB, FRSC, is a distinguished physician-scientist renowned for his extensive contributions to cell biology, genetics, and translational medicine.

Dr. Lisanti commenced his academic journey at New York University, graduating magna cum laude with a Bachelor of Arts in Chemistry in 1985. He then pursued an MD-PhD at Cornell University Medical College, focusing on Cell Biology and Genetics, which he completed in 1992. Following this, he was a Skeggs Fellow at the Whitehead Institute for Biomedical Research at the Massachusetts Institute of Technology (MIT) from 1992 to 1996.

Throughout his career, Dr. Lisanti has held several prominent academic positions. He was a professor at the Albert Einstein College of Medicine from 1997 to 2006 and served at the Kimmel Cancer Center from 2006 to 2012. In 2012, he moved to the United Kingdom to join the University of Manchester as the Muriel Edith Rickman Chair of Breast Oncology and Director of the Breakthrough Breast Cancer Research Unit. In 2016, he assumed the role as the Chair of Translational Medicine at the University of Salford in Manchester, UK.

Dr. Lisanti's research has significantly advanced the understanding of cancer metabolism, particularly through his development of the "reverse Warburg effect," which describes how cancer-associated fibroblasts fuel tumor growth via aerobic glycolysis. His pioneering work has also explored the repurposing of antibiotics, such as doxycycline, to target cancer stem cells, offering promising avenues for cancer treatment.

An accomplished author, Dr. Lisanti has published over 588 peer-reviewed articles, amassing more than 122,000 citations, and holds an h-index 185. He is also the former Editor-in-Chief of The American Journal of Pathology and CELL CYCLE. In recognition of his scientific achievements, Dr. Lisanti has been elected as a Fellow of the Royal Society of Arts (FRSA), the Royal Society of Biology (FRSB), and the Royal Society of Chemistry (FRSC). His ongoing research continues to focus on innovative approaches to cancer treatment, aging, and related diseases, solidifying his reputation as a leading figure in translational medicine.